생물학적 이미징 시약 시장, 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

The Global Biological Imaging Reagents Market will show a 7.3% CAGR between 2024 and 2032, fueled by the rising prevalence of chronic diseases and significant investments in research and development. Factors driving the growth of the Biological Imaging Reagents industry include the rising global health awareness, technological advancements in imaging techniques, and the increasing number of diagnostic imaging procedures. As healthcare systems worldwide emphasize early disease detection and personalized medicine, the demand for advanced imaging reagents has surged. Furthermore, the integration of AI and machine learning in imaging technologies is enhancing diagnostic accuracy, further propelling the growth of the biological imaging reagents market.

Further, the growing use of multimodal imaging techniques is boosting the demand for biological imaging reagents, transforming fields like biomedical research, clinical diagnostics, and therapeutic development. By combining modalities like MRI, PET, CT, and fluorescence microscopy, multimodal imaging offers a clearer and more precise view of biological processes and diseases. This holistic method enhances the identification and understanding of medical conditions, fueling the need for a variety of imaging reagents compatible with multiple modalities.

The overall Biological Imaging Reagents Industry is sorted based on product type, image modality, application, end use, and region.

The biological imaging reagents market is segmented by product type into contrast reagents, optical reagents, and nuclear reagents, with contrast reagents commanding a leading share of 44.8% in 2023. The growing emphasis on early disease detection and personalized medicine is driving the demand for specific imaging agents. As healthcare systems globally prioritize precision in diagnostics, the need for agents that enhance imaging clarity and accuracy becomes paramount. This trend underscores the increasing reliance on advanced imaging techniques in modern medicine.

The biological imaging reagents market's application segments include clinical diagnostics, drug discovery, research, and others, with clinical diagnostics expected to reach USD 9.7 billion by 2032. The rising global health awareness and the push for early disease detection are pivotal in driving the demand for imaging agents. As healthcare systems globally prioritize precision in diagnostics, the need for agents that enhance imaging clarity and accuracy becomes paramount. This trend underscores the increasing reliance on advanced imaging techniques in modern medicine.

North America biological imaging reagents industry, valued at USD 4.7 billion in 2023, is set to grow at a CAGR of 6.9%. North America's biological imaging reagents industry is bolstered by its robust healthcare infrastructure, characterized by state-of-the-art imaging technologies and facilities. This advanced infrastructure not only drives the demand for sophisticated imaging reagents but also positions the region as a leader in biomedical research and innovation. Furthermore, the region's commitment to R&D, backed by substantial public and private investments, accelerates the development and adoption of cutting-edge imaging technologies and reagents.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of chronic conditions
    • 3.2.1.2 Growing adoption of multi-modal imaging
    • 3.2.1.3 Increasing investments in research and development
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent government regulations
• 3.3 Growth potential analysis
• 3.4 Reimbursement scenario
• 3.5 Regulatory landscape
• 3.6 Technological landscape
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Gap analysis
• 3.10 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Contrast reagents
• 5.3 Optical reagents
• 5.4 Nuclear reagents

Chapter 6 Market Estimates and Forecast, By Imaging Modality, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 MRI
• 6.3 Ultrasound
• 6.4 X-ray and CT
• 6.5 Optical imaging
• 6.6 Nuclear imaging
  • 6.6.1 PET
  • 6.6.2 SPECT
  • 6.6.3 Other nuclear imaging modalities

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Clinical diagnostics
  • 7.2.1 Oncology
  • 7.2.2 Cardiology
  • 7.2.3 Neurology
  • 7.2.4 Other clinical diagnostic application
• 7.3 Drug discovery and development
• 7.4 Research and innovation
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Diagnostic imaging centers
• 8.4 Research and academic institutes
• 8.5 Pharmaceutical and biotechnology companies
• 8.6 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Bayer AG
• 10.2 Bracco
• 10.3 Carl Zeiss
• 10.4 Cell Signaling Technology
• 10.5 Danaher
• 10.6 General Electric Company
• 10.7 Guerbet
• 10.8 Jubilant Pharmova Limited
• 10.9 Luminex Corporation
• 10.10 Nikon Corporation
• 10.11 Novartis AG
• 10.12 Olympus Corporation
• 10.13 Promega Corporation
• 10.14 Sartorius AG
• 10.15 Thermo Fisher Scientific Inc.